11/20/20 5:00 PMNasdaq : AUPHAurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)RHEA-AIvery positive
11/12/20 4:05 PMNasdaq : AUPHAurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare ConferenceAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET. In order to participate in the audio webcast, interested parties can register and access the live webcast under "News/Events" through the "Investors" section of the Aurinia corporate webRHEA-AIneutral
11/10/20 4:02 PMNasdaq : AUPHAurinia Reports Third Quarter 2020 Financial Results and Recent Operational HighlightsAurinia Reports Third Quarter 2020 Financial Results and Recent Operational HighlightsRHEA-AIvery positive
11/02/20 4:05 PMNasdaq : AUPHAurinia Announces Outcome of AUDREY(TM) Clinical Trial in Dry Eye SyndromeAurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company, today announced topline data from the Phase 2/3 AUDREY(TM) clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). The trial did not achieve statistical significance on its primary endpoint of a 10mm or greater improvement in STT at four weeks between active doRHEA-AIneutral
10/27/20 4:05 PMNasdaq : AUPHAurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced the funding and initiation of an open-label exploratory trial evaluating the antiviral effects of voclosporin in kidney transplant recipients (KTRs) with COVID-19 (SARS-CoV-2) - the VOCOVID study. The single-center, investigator-initiated trialRHEA-AIneutral
10/22/20 4:15 PMNasdaq : AUPHAurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced that integrated efficacy and pharmacokinetic (PK) data from Aurinia's AURA-LV and AURORA pivotal trials of voclosporin in lupus nephritis (LN) were presented. The data were shared at the American Society of Nephrology (ASN) Kidney Week 2020 in pRHEA-AIneutral
10/14/20 6:05 AMNasdaq : AUPHAurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaign for healthcare professionals (HCPs). The initiative aims to highlight the importance of active screening for early diagnosis to potentially minimize the impact on kidney function and improve long-term outcomes for every patient with LN. "Unfortunately, for many patientRHEA-AIneutral
10/02/20 5:00 PMNasdaq : AUPHAurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company's Compensation Committee granted 9 new employees non-qualified stock options to purchase an aggregate of 96,000 common shares, at a per share exercise price of $14.73 USD, the closing trading price on September 30, 2020. One-third oRHEA-AIvery positive
09/28/20 6:05 AMNasdaq : AUPHAurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye SyndromeAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune conditions, today announced that the last patient study visit has occurred in the Phase 2/3 AUDREY(TM) clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). "Despite the challenges posed by the ongoing viRHEA-AIneutral
